Sage Journals: Discover world-class research

Abstract

Background: Adenoviral gene transfer has been shown to be effective in cardiac myocytes in vitro and in vivo. A major limitation of myocardial gene therapy is the extracardiac transgene expression. Methods: To minimize extracardiac gene expression, we have constructed a tissue-specific promoter for cardiac gene transfer, namely, the 250-bp fragment of the myosin light chain-2v (MLC-2v) gene, which is known to be expressed in a tissue-specific manner in ventricular myocardium followed by a luciferase (luc) reporter gene (Ad.4 × MLC₂₅₀.Luc). Rat cardiomyocytes, liver and kidney cells were infected with Ad.4 × MLC.Luc or control vectors. For in vivo testing, Ad.4 × MLC₂₅₀.Luc was injected into the myocardium or in the liver of rats. Kinetics of promoter activity were monitored over 8 days using a cooled CCD camera. Results: In vitro: By infecting hepatic versus cardiomyocyte cells, we found that the promoter specificity ratio (luc activity in cardiomyocytes per liver cells) was 20.4 versus 0.9 (Ad.4 × MLC₂₅₀.Luc vs. Ad.CMV). In vivo: Ad.4 × MLC₂₅₀.Luc significantly reduced luc activity in liver (38.4-fold), lung (16.1-fold), and kidney (21.8-fold) versus Ad.CMV (p = .01); whereas activity in the heart was only 3.8-fold decreased. The gene expression rate of cardiomyocytes versus hepatocytes was 7:1 (Ad.4 × MLC.Luc) versus 1:1.4 (Ad.CMV.Luc). Discussion: This new vector may be useful to validate therapeutic approaches in animal disease models and offers the perspective for selective expression of therapeutic genes in the diseased heart.

Keywords

Gene therapy cardiac promoters adenovirus

Introduction

Myocardial gene transfer is a promising tool to target specific abnormalities of the failing heart. Using adenoviral vectors, we recently demonstrated that over-expression of sarcoplasmic reticulum Ca(2+)-ATPase (SERCA2a) not only improves contractility [1,2] but also survival [3] in animals with heart failure. However, a major limitation of adenoviral in vivo gene transfer into the myocardium is the expression of transgenes in other organs due to the systemic distribution of virus. Adenoviral constructs show a native tropism for hepatic tissue, but are also found in the lung, thymus, brain, and kidney, regardless of the viral delivery technique [4,5]. This undesired transgene expression may exhibit potential side effects such as inflammation and cell apoptosis in noncardiac tissues, raising important safety concerns [6,7]. A variety of strategies has evolved to overcome these obstacles. Modifying the viral construct itself turned out to be crucial for increasing organ specificity. Once the virus is in the cell nucleus, the actual expression of the transgene is maintained by its promoter, since these viral regulatory elements are responsible for starting transcription of the delivered transgene. Controlling gene expression with a promoter specific to cardiac tissue could avoid transgene activation in other tissues than the heart. Several different cardiospecific promoters have been investigated so far, including α-myosin heavy chain (α-MHC), atrial natriuretic peptide (ANP), and myosin light chain-2v (MLC-2v) promoters [8,9]. In tissue culture experiments, the myosin light chain (MLC-2v) promoter promises high tissue specificity [10]. We hypothesize that alterations in the 250 base pair (250-bp) fragment of the promoter construct may improve the tissue specificity to a point that in vivo cardioselective gene transfer becomes feasible. The present study investigates whether an adenoviral vector driven by an enhanced cardiospecific promoter construct can result in selective transgene expression in rat hearts without significant expression in other organs. To test whether different gene delivery techniques affect promoter activity and specificity, viral constructs are evaluated using localized and systemic myocardial delivery techniques.

Studies of cardiac gene transfer usually rely on postmortem analysis, thus making an assessment of the temporal dynamics of transgene distribution extremely difficult. Optical imaging of myocardial transgene expression in live animals is a relatively new technique, and its application to evaluate temporal and spatial characteristics of cardiac gene expression in the same animal offers significant advantages [11,12]. In this experiment, we use a cooled charged couple detector (CCD) camera to detect and quantify the dynamic course of gene expression rate efficacy and organ specificity of a new cardiospecific promoter fused with a firefly luciferase reporter gene.

Materials and Methods

Promoter Construction

4 × MLC₂₅₀ promoter. The 250-bp fragment of the 5′ regulatory region of the rat MLC-2v gene (kindly provided by Dr. Nadia Rosenthal, EMBL Rome, Italy) was cut using BGLII and KPNI from a PGL2 vector was cloned into a Bluescript vector (Invitrogen, California). A second fragment of the MLC promoter fragment, containing the regulatory sequences (HF-3, MLE-1, HF-2, E-box, HF-1a, and HF-1b/MEF-2), but lacking the 3′ transcription initiation site of the promoter (including TATA-box), was ligated with the 5′ end of the 250-bp promoter fragment. The fusion product was used to generate a construct of four copies of the 250 bp promoter fragment MLC-2v promoter. 4 × MLC₂₅₀ bp promoter fragment, Luciferase and SV40 poly(A) signal were subcloned into the adenoviral shuttle vector pAdTrack. As positive controls, a CMV promoter fragment (800 bp) controlling luciferase gene expression was used, and the full-length MLC-2v promoter was used. A promoter-less luciferase construct (containing only the luciferase gene without a promoter) was generated as negative control.

Generation of Adenovirus

Adenoviruses have been generated as previously described [13]. Briefly, the different plasmids were recombined in Escherichia coli (BJ5183), together with a serotype 5 first-generation adenoviral backbone (pAdEasy-1). Successfully recombined viral clones were transfected into 293 cells. Viral stocks of 3–5 × 10¹¹ plaque-forming units (pfu) per mL with a particle/pfu ratio of 10² were generated for in vitro and in vivo experiments. Viral concentration was determined by plaque assay.

Gene Transfer In Vitro

LLC-PK1 cells (kindly provided by Dr. Joseph Bonventre, Department of Medicine, Massachusetts General Hospital) were maintained in culture at 95% air, 5% CO₂ at 37°C in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum. HepG2 cells and COS cells were cultured according to standard protocols. Cardiomyocytes were prepared from 1- to 2-day-old rats by use of the Neonatal Cardiomyocyte Isolation System (Worthington Biochemical, New Jersey), plated in six-well plates at 5 × 10⁵ cells/well, and cultured in RPMI 1640/5% FCS/10% horse serum (HS). After 72 hr, cells were incubated with or without adenoviral vector for 48 hr at a multiplicity of infection (MOI) of 10 pfu/cell. Cells were harvested, washed with PBS, and were processed for luciferase assay according to the protocol (Promega, Wisconsin).

Gene Transfer In Vivo

All animals received humane care in compliance with the “Guide for the Care and Use of Laboratory Animals” published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).

Direct injection. In vivo gene transfer was performed on male Sprague–Dawley rats (200–250 g, Charles River, Massachussetts) by injection of 100 μL viral solution (5 × 10⁹ pfu) in the left ventricular apex or into the left liver lobe. Animals that underwent subsequent optical imaging were injected with 50 μL (5 × 10⁹ pfu) viral solution into the anterolateral wall of the left ventricle.

Coronary perfusion. To evaluate whether a delivery technique aiming at global heart gene expression rate can further improve cardiac specificity, in a subset of animals a 22-gauge catheter was advanced from the apex of the left ventricle to the aortic root and 200 μL viral solution (5 × 10⁹ pfu) were injected while cross-clamping the aorta and pulmonary artery for 40 sec.

Optical Imaging of Transgene Expression

The Xenogen In Vivo Imaging System (IVIS) consists of a cooled CCD camera mounted on a light-tight specimen chamber, a cryogenic refrigeration unit, a camera controller, and a computer system for data analysis. Both the IVIS and its imaging analysis software are commercially available (Xenogen, New Jersey). Transgene bioluminescence was imaged in vivo as previously described [11,14]. After intraperitoneal injection of reporter substrate d-luciferin (125 mg/kg body weight), serial images were acquired over 20 min every 2 to 8 days. The bioluminescence was quantified as reported previously [14].

Luciferase Assay and Evaluation of Gene Expression Rate Efficiency

After sacrifice, organs (heart, liver, lung, kidney) were dissected and immediately frozen in liquid nitrogen. Samples were weighed, homogenized in lysis buffer (1% (v/v) Triton X-100, 10% glycerol, 25 mM Trisphosphate pH 7.8, 2 mM DTT) and centrifuged. The supernatant was used to perform luciferase assays as reported elsewhere [15].

Table 1.

Luciferase Activity Given in RLU/mg

	Ad.CMV.Luc	Ad.4 × MLC₂₅₀.Luc	Ad.MLC-2v.Luc	Ad.Luc

Cardiomyocytes	238,462 ± 15,385	49,230 ± 7690	33,210 ± 5770*	1201 ± 527
HepG2	246,154 ± 29,231	2410 ± 322	3215 ± 309	872 ± 299
LLC-PK1	284,615 ± 30,770	5377 ± 211	8202 ± 1553	705 ± 463
COS	638,462 ± 46,154	14,511 ± 579	12,821 ± 2902	1052 ± 892

Five groups of 10⁵ cells were used for each experiment.

p < .01 compared with Ad.4 × MLC₂₅₀.Luc group.

Statistics

Comparisons between groups were carried out using a two-tailed Student's t test. Statistical significance was accepted at a value of p < .05. Luciferase activities from in vivo CCD imaging and in vitro luminometer assays were correlated by least-squares linear regression. All data are expressed as arithmetic means ± standard error of the mean (SEM).

Results

Gene Transfer In Vitro

To evaluate cell-type specific expression and relative promoter-strength in vitro, rat neonatal cardiomyocytes, HepG2 cells, kidney cell line LLC-PK1, and COS cells were infected with the viral constructs Ad.4 × MLC₂₅₀.Luc, Ad.CMV.Luc, Ad.MLC2v.Luc, and Ad.Luc, respectively, at a multiplicity of infection of 10 (10 pfu/cell). In rat neonatal cardiomyocytes, infection with Ad.4 × MLC. Luc resulted in a 4.8-fold lower luciferase expression than with the CMV promoter. However, in noncardiac cells, luciferase expression was significantly reduced under the control of the 4 × MLC promoter compared with the CMV promoter as shown in Table 1. In HepG2 cells Ad.4 × MLC₂₅₀.Luc was found to have reduced luciferase activity by 103-fold compared with the CMV promoter. Similar results were found in the LLC-PK1 kidney cells and COS cells (53-fold and 44-fold reduction with 4 × MLC250, respectively). Cells infected with the promoter-less construct Ad.Luc showed only background activity. We also found that the full-length promoter MLC-2v had lower activity than the 4 × MLC250 promoter with also a higher specificity when compared with HepG2 and LLC-PK1 cells.

Gene Transfer In Vivo

Coronary Perfusion. Coronary circulation was perfused with the virus constructs Ad.4 × MLC₂₅₀.Luc (n = 18), Ad.CMV.Luc (n = 14), and Ad.Luc (n = 14). Myocardium transfected with Ad.4 × MLC₂₅₀.Luc showed a 3.8-fold lower luciferase activity compared with the Ad.CMV.Luc group. 4 × MLC250 promoter significantly reduced the transgene activity in other organs (liver 38.4.-fold, lung 16.1-fold, kidney 21.8-fold; p < .01) versus the nonspecific CMV promoter (Figure 1). The myocardial specificity ratio of the 4 × MLC promoter was higher than the CMV promoter in all other organs (4 × MLC vs. CMV; heart/liver 7.0 vs. 0.7, heart/lung 20.7 vs. 4.9, heart/kidney 43.9 vs. 7.8) (Figure 2). The promoter-less construct Ad.Luc showed only background activity (data not shown). Direct Intramyocardial Injection. To reduce the effects of direct systemic tissue distribution, Ad.4 × MLC₂₅₀.Luc, Ad.CMV.Luc, or Ad.Luc were directly injected into the left ventricular myocardium (n = 10). After intramyocardial injection of adenoviral constructs, the myocardium showed robust luciferase activity under control of both promoters (Ad.CMV.Luc = 1,721,220 ± 267,101; Ad.4 × MLC₂₅₀.Luc = 277,780 ± 67,721 RLU/mg). Although the 4 × MLC promoter resulted in reduced myocardial luciferase activity 6.2-fold compared to the CMV promoter, it reduced luciferase activity 131-fold in liver tissue of the same animals (Ad.CMV.Luc = 807,100 ± 215,338; Ad.4 × MLC₂₅₀.Luc = 6,162 ± 672 RLU/mg).

Figure 1.

Gene expression after coronary perfusion in vivo after direct myocardial injection. Luciferase activity in four different organs harvested 3 days after coronary perfusion with Ad.CMV.Luc (gray bars) or Ad.4 × MLC₂₅₀.Luc (black bars).

Figure 2.

(A) Time variation of myocardial specificity ratio. Both groups show a loss in myocardial specificity over time. Animals transduced with Ad.CMV.Luc show a 50-fold decrease in myocardial specificity between Day 5 and Day 8 (solid line). In contrast, myocardial specificity of animals transduced with Ad.4 × MLC₂₅₀−2v.Luc decreased only 2-fold after Day 5 (dashed line). (B) Optical imaging of hepatic luciferace activity. Promoter activity in the liver shows a continuous increase in rats transduced with Ad.CMV.Luc (solid line). Animals receiving Ad.4 × MLC-2v.Luc showed a peak hepatic activity at Day 5 with a subsequent decrease of promoter activity to baseline levels (dashed line).

Direct Intrahepatic Injection. To directly evaluate cardiac specificity of the 4 × MLC₂₅₀ promoter in other organs than the heart, both constructs were injected in the left liver lobe. Although Ad.4 × MLC.Luc induced luciferase expression in hepatic tissue, transgene activity was 88.5-times lower compared with the Ad.CMV.Luc group (3.829 ± 88 vs. 43 ± 9 RLU/mg [× 10³]; Ad.CMV. Luc vs. Ad.4 × MLC₂₅₀.Luc).

Optical Imaging of Transgene Expression. Rats (n = 10) were scanned on Days 0, 2, 5, and 8 after direct myocardial injection of Ad.4 × MLC₂₅₀.Luc or Ad.CMV.Luc to monitor the kinetics of transgene expression (Figure 3). Both groups showed robust luciferase activity at 2, 5, and 8 days. While both promoters showed a loss in myocardial specificity over time, the CMV promoter showed a 50-fold decrease in myocardial specificity between Day 5 and Day 8. In contrast, myocardial specificity of the 4 × MLC₂₅₀ promoter decreased only 2-fold after Day 5 (Figure 2A). Promoter activity in the liver showed a continuous increase in rats transduced with Ad.CMV.Luc, whereas animals receiving Ad.4 × MLC₂₅₀.Luc showed a peak hepatic activity at Day 5 with a subsequent decrease of promoter activity (Figure 2B).

Discussion

Adenoviruses have become one of the main vectors for gene transfer, mainly due to their high gene expression rate efficiency [16]. Unlike commonly used drugs, viral vectors not only reach the heart but also other major organs including the liver, kidney, and lung, exhibiting potential serious side effects.

A variety of cardiospecific promoters have been investigated to address this problem, including atrial natriuretic factor (ANF) [9], cardiac troponin T (TnT) [17], alpha-myosin heavy chain (MHC) [8], and myosin light chain-2 (MLC-2v) [8,10,18]. We concentrated our efforts on the MLC-2v promoter because in vitro studies have indicated that this promoter sequence shows a higher restriction to cardiac tissue than other promoters tested [8]. A conserved 28-bp element (HF-1-3) within the rat cardiac MLC-2v gene has been shown to confer cardiac muscle-specific gene expression [19]. We therefore constructed a promoter hybrid containing four copies of the MLC-2v promoter element HF-1-3. (4 × MLC₂₅₀) to amplify this cardiospecific expression.

Myocardial Promoter Activity

Evaluation of gene expression rate of a new promoter construct is fundamental for proper promoter assessment. Although many investigators demonstrate promoter characteristics regarding its restriction to myocardial cells, only very few studies show a quantitative assessment of promoter activity in myocardium and other tissues both in vitro and in vivo [8]. A study by Franz et al. [8] observed a 10-fold reduction of myocardial gene expression rate by using an unaltered full-length MLC-2v promoter versus the RSV promoter. Our results show that the newly constructed 4 × MLC₂₅₀ promoter causes a 4–6-fold lower myocardial gene expression rate when compared with the CMV promoter after coronary perfusion or direct myocardial virus delivery, however, it shows a higher myocardial promoter activity; these results support an inversely proportional relationship between tissue specificity and promoter strength.

Figure 3.

Optical imaging of reporter gene expression. Animals imaged on Day 2 (top) and Day 5 (bottom) after cardiac gene transfer. Both rats emit significant myocardial luciferase activity at Day 2 and Day 5. Animal transfected with Ad.CMV.Luc shows prominent hepatic luciferase activity starting at Day 5. Control rat shows background signal. Note that the bioluminescent scales are different for control rat, Ad. CMV.Luc and Ad. 4 × MLC₂₅₀−2v.Luc to account for the wide range of cardiac luciferase activity observed.

Myocardial Specificity

Although exogenous viral promoters such as CMV are active in a wide range of tissues, it has been reported that CMV promoters show a particular tropism to hepatic tissue [4,5]. This effect has been attributed to significant side effects of adenoviral gene transfer [6,7]. We here introduce a myocardial specificity ratio (myocardial promoter activity/hepatic promoter activity) to approximate the effects and side effects of different promoters in vivo and in vitro. A myocardial specificity ratio > 1 indicates a higher myocardial than hepatic promoter activity. Not surprisingly, coronary perfusion of virus caused the highest amount of virus distribution in the systemic circulation, resulting in a myocardial specificity ratio of 7 versus 0.7 (4 × MLC₂₅₀ vs. CMV). Although 4 × MLC shows a 10-fold reduction in hepatic tropism versus CMV, this result indicates that the use of coronary perfusion techniques even with cardiospecific promoters may involve more risks than other more localized gene delivery methods.

Temporal Characteristics of Promoter Activity

Recently, Wu et al. [11] could show that optical imaging of cardiac reporter genes is feasible in living rats. In this experiment, we extended the use of optical imaging in rats to monitor and compare temporal changes of myocardial promoter specificity. In accordance with the common dynamics of adenoviral mediated transgene expression [20,21], both promoters showed a loss of myocardial activity over time, with its greatest activity at Day 5. Although this dynamics could also be observed in hepatic activity of the 4 × MLC₂₅₀ promoter, the CMV promoter showed a constant increase in hepatic transgene activity until Day 8, causing a dramatic loss of its myocardial specificity ratio (50-fold vs. 2-fold; CMV vs. 4 × MLC₂₅₀). This late increase in hepatic transgene activity can be explained this way: (1) a cumulative leakage of adenovirus from the myocardium after direct myocardial injection, leading to a predominantly hepatic gene expression rate [11]; (2) adenoviral constructs show a native tropism for hepatic tissue, irrespective of the promoter used [22,23]; and (3) transgene expression was finally facilitated by a nonspecific promoter (CMV). In contrast, the newly established 4 × MLC₂₅₀ promoter was able to mainly preserve its myocardial specificity ratio from Day 5 to Day 8, counteracting the abovementioned obstacles.

In this study, we evaluated a new cardiospecific promoter in vivo and vitro. 4 × MLC₂₅₀ is highly selective for myocardial tissue and shows a significantly higher myocardial specificity ratio in vivo and in vitro than a nonspecific CMV promoter. Although the 4 × MLC₂₅₀ promoter was not exclusively active in myocardial tissue, we could demonstrate that 4 × MLC₂₅₀ greatly reduces late hepatic transgene activation, thus lessening an important safety concern after intracardiac gene transfer. Our results provide evidence that tissue-specific promoters may be successfully enhanced, and will play an important role in the quest for safer viral gene transfer.

Footnotes

Acknowledgments

This work was supported in part by grants from the National Institutes of Health: HL 57623, HL 71763, HL73375, (R. J. H.); HL069842 (F. dM), HL 697782 (U. S.) and the Older Americans Independence Center (U. S.). O. Y. B. is supported by a grant from the Max Kade Foundation, New York. R. J. H. is a Paul Beeson scholar of the American Federation of Aging Research.

References

Miyamoto

del Monte

Schmidt

DiSalvo

Kang

Matsui

Guerrero

Gwathmey

Rosenzweig

Hajjar

(2000). Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proc Natl Acad Sci USA. 97:793–798.

Schmidt

del Monte

Miyamoto

Matsui

Gwathmey

Rosenzweig

Hajjar

(2000). Restoration of diastolic function in senescent rat hearts through adenoviral gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase. Circulation. 101:790–796.

del Monte

Williams

Lebeche

Schmidt

Rosenzweig

Gwathmey

Lewandowski

Hajjar

(2001). Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure. Circulation. 104:1424–1429.

Hiltunen

Turunen

Rissanen

Laitinen

Kosma

Yla-Herttuala

(2000). Biodistribution of adenoviral vector to nontarget tissues after local in vivo gene transfer to arterial wall using intravascular and periadventitial gene delivery methods. FASEB J. 14:2230–2236.

Fechner

Haack

Wang

Eizema

Pauschinger

Schoemaker

Veghel

Houtsmuller

Schultheiss

Lamers

Poller

(1999). Expression of coxsackie adenovirus receptor and alpha_v-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers. Gene Ther. 6:1520–1535.

Muhlhauser

Jones

Yamada

Cirielli

Lemarchand

Gloe

Bewig

Signoretti

Crystal

Capogrossi

(1996). Safety and efficacy of in vivo gene transfer into the porcine heart with replication-deficient, recombinant adenovirus vectors. Gene Ther. 3:145–153.

Ginsberg

(1996). The ups and downs of adenovirus vectors. Bull NY Acad Med. 73:53–58.

Franz

Rothmann

Frey

Katus

(1997). Analysis of tissue-specific gene delivery by recombinant adenoviruses containing cardiac-specific promoters. Cardiovasc Res. 35:560–566.

Eizema

Fechner

Bezstarosti

Schneider-Rasp

van der Laarse

Wang

Schultheiss

Poller

Lamers

(2000). Adenovirus-based phospholamban antisense expression as a novel approach to improve cardiac contractile dysfunction: Comparison of a constitutive viral versus an endothelin-1-responsive cardiac promoter. Circulation. 101:2193–2199.

10.

Rothmann

Katus

Hartong

Perricaudet

Franz

(1996). Heart muscle-specific gene expression using replication defective recombinant adenovirus. Gene Ther. 3:919–926.

11.

Inubushi

Sundaresan

Schelbert

Gambhir

(2002). Optical imaging of cardiac reporter gene expression in living rats. Circulation. 105:1631–1634.

12.

Honigman

Zeira

Ohana

Abramovitz

Tavor

Bar

Zilberman

Rabinovsky

Gazit

Joseph

Panet

Shai

Palmon

Laster

Galun

(2001). Imaging transgene expression in live animals. Mol Ther. 4:239–249.

13.

Zhou

da Costa

Kinzler

Vogelstein

(1998). A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA. 95:2509–2514.

14.

Sundaresan

Iyer

Gambhir

(2001). Noninvasive optical imaging of firefly luciferase reporter gene expression in skeletal muscles of living mice. Mol Ther. 4:297–306.

15.

Manthorpe

Cornefert-Jensen

Hartikka

Felgner

Rundell

Margalith

Dwarki

(1993). Gene therapy by intramuscular injection of plasmid DNA: Studies on firefly luciferase gene expression in mice. Hum Gene Ther. 4:419–431.

16.

Isner

(2002). Myocardial gene therapy. Nature. 415:234–239.

17.

Inesi

Lewis

Sumbilla

Nandi

Strock

Huff

Rogers

Johns

Kessler

Ordahl

(1998). Cell-specific promoter in adenovirus vector for transgenic expression of SERCA1 ATPase in cardiac myocytes. Am J Physiol. 274:C645–C653.

18.

Griscelli

Gilardi-Hebenstreit

Hanania

Franz

Opolon

Perricaudet

Ragot

(1998). Heart-specific targeting of beta-galactosidase by the ventricle-specific cardiac myosin light chain 2 promoter using adenovirus vectors. Hum Gene Ther. 9:1919–1928.

19.

Lee

Hickey

Zhu

Chien

(1994). Positive regulatory elements (HF-1a and HF-1b) and a novel negative regulatory element (HF-3) mediate ventricular muscle-specific expression of myosin light-chain 2-luciferase fusion genes in transgenic mice. Mol Cell Biol. 14:1220–1229.

20.

Gilgenkrantz

Duboc

Juillard

Couton

Pavirani

Guillet

Briand

Kahn

(1995). Transient expression of genes transferred in vivo into heart using first-generation adenoviral vectors: Role of the immune response. Hum Gene Ther. 6:1265–1274.

21.

Kass-Eisler

Falck-Pedersen

Alvira

Rivera

Buttrick

Wittenberg

Cipriani

Leinwand

(1993). Quantitative determination of adenovirus-mediated gene delivery to rat cardiac myocytes in vitro and in vivo. Proc Natl Acad Sci USA. 90:11498–11502.

22.

Connelly

(1999). Adenoviral vectors for liver-directed gene therapy. Curr Opin Mol Ther. 1:565–572.

23.

Wilson

(2001). Adenovirus-mediated gene transfer to liver. Adv Drug Deliv Rev. 46:205–209.

Cardiac-Specific Gene Expression Facilitated by an Enhanced Myosin Light Chain Promoter

Abstract

Keywords

Introduction

Materials and Methods

Promoter Construction

Generation of Adenovirus

Gene Transfer In Vitro

Gene Transfer In Vivo

Optical Imaging of Transgene Expression

Luciferase Assay and Evaluation of Gene Expression Rate Efficiency

Statistics

Results

Gene Transfer In Vitro

Gene Transfer In Vivo

Discussion

Myocardial Promoter Activity

Myocardial Specificity

Temporal Characteristics of Promoter Activity

Footnotes

Acknowledgments

References